Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trough level-based infliximab dose reduction in Crohn's disease
2013-001029-17Phase 4Active
- Sponsor
- Academic Medical Center
- Start
- May 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of infliximab in Crohn's disease (2 arms), sponsored by Academic Medical Center. Primary endpoint: Sustained clinical remission. Started May 2013; status: active.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2013-001029-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001029-17.